Immunotherapy Outcomes in Individuals With Non–Small Cell Lung Cancer and Poor Performance Status

BACKGROUND: Patients with non–small cell lung cancer (NSCLC) treated in real-world practice typically have worse performance status (PS) compared with clinical trial patients, and the effectiveness of immunotherapy in this population in unknown. In this study, we assessed the effectiveness of standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Veluswamy, Rajwanth, Hu, Liangyuan, Smith, Cardinale, Ji, Jiayi, Wang, Xiaoliang, Wisnivesky, Juan, Morillo, Jose, Kale, Minal S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921740/
https://www.ncbi.nlm.nih.gov/pubmed/35603847
http://dx.doi.org/10.1093/jncics/pkac013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921740/
https://www.ncbi.nlm.nih.gov/pubmed/35603847
http://dx.doi.org/10.1093/jncics/pkac013

Ejemplares similares